What is LLY stock price today?

LLY (Eli Lilly & Co) stock is trading at $1051.99 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is LLY stock going up or down today?

LLY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy LLY stock now?

The decision to buy LLY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is LLY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for LLY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is LLY stock overvalued or undervalued?

LLY currently trades at a P/E ratio of 45.88, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if LLY is fairly priced.

What is LLY's P/E ratio?

LLY has a price-to-earnings (P/E) ratio of 45.88, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is LLY's market cap?

LLY (Eli Lilly & Co) has a market capitalization of $992.40 billion, making it a large-cap stock.

What is LLY's price to book ratio?

LLY trades at a price-to-book (P/B) ratio of 36.33, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does LLY pay dividends?

Yes, LLY pays dividends with a current yield of 0.01%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is LLY's dividend yield?

LLY's dividend yield is 0.01%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is LLY stock a good long-term investment?

LLY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is LLY's revenue growth rate?

LLY has shown revenue growth of 0.4% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, LLY is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in LLY?

Key risks for LLY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does LLY compare to its competitors?

Compare LLY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize LLY's performance and positioning.

What is LLY's stock price target for 2026?

Our AI model provides price targets for LLY based on fundamental analysis: Bull case $1367.59 (+30%), Base case $1209.79 (+15%), Bear case $946.79 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about LLY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for LLY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is LLY's next earnings report?

LLY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

LLY - Eli Lilly & Co

NYSE * Health Care * Pharmaceuticals

$1.05K

+$29.97 (+2.93%)

About Eli Lilly & Co

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

LLY Key Statistics

Market Cap

$992.40B

P/E Ratio

45.88

P/B Ratio

36.33

EPS

$22.93

Dividend Yield

0.01%

Revenue Growth

+0.4%

Profit Margin

0.3%

Employees

50,000

How LLY Compares to Peers

LLY trades at a premium valuation vs peers (highest P/E)

LLY has the highest profit margins in Pharmaceuticals

LLY has the fastest revenue growth among competitors

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
LLY(This stock)	$992.40B	45.9	0%	0.3%	-
AMZNAmazon Com	$2.25T	29.3	0%	0.1%	vs AMZN

Eli Lilly & Co Company Information

Headquarters: Indiana; U.S.A
Website: www.lilly.com
Sector: Health Care
Industry: Pharmaceuticals

LLY - Eli Lilly & Co

About Eli Lilly & Co

LLY Key Statistics

How LLY Compares to Peers

Eli Lilly & Co Company Information

LLY Lician Score

LLY Financial Snowflake

Upcoming Events for LLY